72-57-1

• 常用中文名：直接蓝 14
• 常用英文名：Direct Blue 14
• CAS号：72-57-1
• 分子式：C₃₄H₂₄N₆Na₄O₁₄S₄
• 分子量：960.805
• 相关类别： 有机原料 氨基化合物 磺酸类氨基化合物
• 发布时间：2018-02-18 08:00:00
• 更新时间：2024-01-07 10:18:58
• Diphenyl Blue (Direct Blue 14) 是用作偶氮染料组的参考染料。

名称

• 中文名: 曲利苯蓝
• 英文名: trypan blue
• 中文别名: 直接蓝 14; 台盼蓝; 曲利苯兰; 锥虫蓝; 锥虫兰
• 英文别名: parkipan; Direct Blue 14; 2,7-Naphthalenedisulfonic acid, 3,3'-[(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)di(E)-2,1-diazenediyl]bis[5-amino-4-hydroxy-, sodium salt (1:4); Tetrasodium 3,3'-[(3,3'-Dimethyl-4,4'-biphenylene)bis(azo)]bis(5-amino-4-hydroxy-2,7-naphthalenedisulfonate); Trypan blue; MFCD00003969; Tetrasodium 3,3'-[(3,3'-dimethyl-4,4'-biphenyldiyl)di(E)-2,1-diazenediyl]bis(5-amino-4-hydroxy-2,7-naphthalenedisulfonate); blue3b; TRUE BLUE; benzoblue; EINECS 200-786-7; parkibleu; blueemb; 3,3'-[(3,3'-Dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[5-amino-4-hydroxy-2,7-naphthalenedisulfonic Acid] Tetrasodium Salt; congoblue; 3,3'-[(3,3'-Dimethyl-4,4'-biphenylene)bis(azo)]bis(5-amino-4-hydroxy-2,7-naphthalenedisulfonic Acid) Tetrasodium Salt; Diamine Blue; trypan; Benzamine Blue; Tetrasodium 3,3'-[(3,3'-dimethylbiphenyl-4,4'-diyl)di(E)diazene-2,1-diyl]bis(5-amino-4-hydroxynaphthalene-2,7-disulfonate); Diphenyl Blue

物化性质

• 密度: 1.007 g/mL at 20 °C
• 熔点: >300 °C(lit.)
• 分子式: C₃₄H₂₄N₆Na₄O₁₄S₄
• 分子量: 960.805
• 精确质量: 959.982422
• PSA: 404.26000
• LogP: 10.78520
• 外观性状: 蓝色-灰色粉末
• 储存条件:

  本品应密封阴凉干燥保存。

• 水溶解性: 10 g/L (25 ºC)
• 计算化学:

  1、 氢键供体数量：4

  2、 氢键受体数量：20

  3、 可旋转化学键数量：5

  4、 互变异构体数量：231

  5、 拓扑分子极性表面积（TPSA）：364

  6、 重原子数量：62

  7、 表面电荷：0

  8、 复杂度：2030

  9、 同位素原子数量：0

  10、 确定原子立构中心数量：0

  11、 不确定原子立构中心数量：0

  12、 确定化学键立构中心数量：2

  13、 不确定化学键立构中心数量：0

  14、 共价键单元数量：5

• 更多:

  1. 性状：蓝灰色粉状物

  2. 密度（g/mL,25/4℃）：不确定

  3. 相对蒸汽密度（g/mL,空气=1）：不确定

  4. 熔点（ºC）：>300

  5. 沸点（ºC,常压）：不确定

  6. 沸点（ºC, 5.2 kPa）：不确定

  7. 折射率：不确定

  8. 闪点（ºC）：不确定

  9. 比旋光度（º）：不确定

  10. 自燃点或引燃温度（ºC）：不确定

  11. 蒸气压（kPa,25 ºC）：不确定

  12. 饱和蒸气压（kPa,60 ºC）：不确定

  13. 燃烧热（KJ/mol）：不确定

  14. 临界温度（ºC）：不确定

  15. 临界压力（KPa）：不确定

  16. 油水（辛醇/水）分配系数的对数值：不确定

  17. 爆炸上限（%,V/V）：不确定

  18. 爆炸下限（%,V/V）：不确定

  19. 溶解性：溶于水，微溶于乙醇，不溶于其他有机溶剂

生物活性

• 描述: Diphenyl Blue (Direct Blue 14) 是用作偶氮染料组的参考染料。
• 相关类别:
  信号通路 >> 其他 >> 其他
  染料试剂
  研究领域 >> 其他

MSDS

1.1 产品标识符 : 台盼蓝 溶液 产品名称 1.2 鉴别的其他方法 无数据资料 1.3 有关的确定了的物质或混合物的用途和建议不适合的用途 仅供科研用途，不作为药物、家庭备用药或其它用途。 模块2. 危险性概述 2.1 GHS分类 致癌性 (类别1B) 2.2 GHS 标记要素，包括预防性的陈述 象形图 警示词危险 危险申明 H350可能致癌。 警告申明 预防 P201在使用前获取特别指示。 P202在读懂所有安全防范措施之前切勿操作。 P281使用所需的个人防护设备。 措施 P308 + P313如接触到或有疑虑：求医/ 就诊。 储存 P405存放处须加锁。 处理 P501将内容物/ 容器处理到得到批准的废物处理厂。 只限于专业使用者。 2.3 其它危害物 - 无 模块3. 成分/组成信息 3.2 混合物 : C34H24N6Na4O14S4 分子式 : 960.81 g/mol 分子量 组分分类浓度或浓度范围 Tetrasodium 3,3'-[(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[5-amino-4-hydroxynaphthalene-2,7- disulphonate] CAS 号72-57-1Carc. 1B; H3500.25 - 0.5 % EC-编号200-786-7 索引编号611-024-00-1 如需在本章节中提及的H类告知和R类描述的全部文字说明,请见第16章节. 模块4. 急救措施 4.1 必要的急救措施描述 一般的建议 请教医生。 出示此安全技术说明书给到现场的医生看。 吸入 如果吸入,请将患者移到新鲜空气处。 如果停止了呼吸,给于人工呼吸。 请教医生。 皮肤接触 用肥皂和大量的水冲洗。 请教医生。 眼睛接触 用水冲洗眼睛作为预防措施。 食入 切勿给失去知觉者从嘴里喂食任何东西。 用水漱口。 请教医生。 4.2 主要症状和影响，急性和迟发效应 据我们所知，此化学，物理和毒性性质尚未经完整的研究。 4.3 及时的医疗处理和所需的特殊处理的说明和指示 无数据资料 模块5. 消防措施 5.1 灭火介质 灭火方法及灭火剂 用水雾,耐醇泡沫,干粉或二氧化碳灭火。 5.2 源于此物质或混合物的特别的危害 产品分解后性质不明 5.3 给消防员的建议 如必要的话,戴自给式呼吸器去救火。 5.4 进一步信息 无数据资料 模块6. 泄露应急处理 6.1 人员的预防,防护设备和紧急处理程序 使用个人防护设备。 防止吸入蒸汽、气雾或气体。 保证充分的通风。 将人员撤离到安全区域。 6.2 环境保护措施 在确保安全的前提下，采取措施防止进一步的泄漏或溢出。 不要让产物进入下水道。 6.3 抑制和清除溢出物的方法和材料 用惰性吸附材料吸收并当作危险废品处理。 存放进适当的闭口容器中待处理。 6.4 参考其他部分 丢弃处理请参阅第13节。 模块7. 操作处置与储存 7.1 安全操作的注意事项 避免曝露：使用前需要获得专门的指导。防止吸入蒸汽和烟雾。 7.2 安全储存的条件,包括任何不兼容性 贮存在阴凉处。 容器保持紧闭，储存在干燥通风处。 打开了的容器必须仔细重新封口并保持竖放位置以防止泄漏。 7.3 特定用途 无数据资料 模块8. 接触控制和个体防护 8.1 容许浓度 最高容许浓度 没有已知的国家规定的暴露极限。 8.2 暴露控制 适当的技术控制 按照良好工业和安全规范操作。 休息前和工作结束时洗手。 个体防护设备 眼/面保护 带有防护边罩的安全眼镜符合 EN166要求请使用经官方标准如NIOSH (美国) 或 EN 166(欧盟) 检测与批准的设备防护眼部。 皮肤保护 戴手套取 手套在使用前必须受检查。 请使用合适的方法脱除手套(不要接触手套外部表面),避免任何皮肤部位接触此产品. 使用后请将被污染过的手套根据相关法律法规和有效的实验室规章程序谨慎处理. 请清洗并吹干双手 所选择的保护手套必须符合EU的89/686/EEC规定和从它衍生出来的EN 376标准。 身体保护 全套防化学试剂工作服, 防护设备的类型必须根据特定工作场所中的危险物的浓度和含量来选择。 呼吸系统防护 如危险性评测显示需要使用空气净化的防毒面具，请使用全面罩式多功能防毒面具（US）或ABEK型 （EN 14387）防毒面具筒作为工程控制的候补。如果防毒面具是保护的唯一方式，则使用全面罩式送风防 毒面具。 呼吸器使用经过测试并通过政府标准如NIOSH（US）或CEN（EU）的呼吸器和零件。 模块9. 理化特性 9.1 基本的理化特性的信息 a) 外观与性状 形状: 液体 b) 气味 无数据资料 c) 气味阈值 无数据资料 d) pH值 无数据资料 e) 熔点/凝固点 无数据资料 f) 起始沸点和沸程 无数据资料 g) 闪点 无数据资料 h) 蒸发速率 无数据资料 i) 易燃性(固体,气体) 无数据资料 j) 高的/低的燃烧性或爆炸性限度 无数据资料 k) 蒸汽压 无数据资料 l) 蒸汽密度 无数据资料 m) 相对密度 无数据资料 n) 水溶性 无数据资料 o) n-辛醇/水分配系数 无数据资料 p) 自燃温度 无数据资料 q) 分解温度 无数据资料 r) 粘度 无数据资料 模块10. 稳定性和反应活性 10.1 反应性 无数据资料 10.2 稳定性 无数据资料 10.3 危险反应的可能性 无数据资料 10.4 应避免的条件 无数据资料 10.5 不兼容的材料 强氧化剂 10.6 危险的分解产物 其它分解产物 - 无数据资料 模块11. 毒理学资料 11.1 毒理学影响的信息 急性毒性 无数据资料 皮肤刺激或腐蚀 无数据资料 眼睛刺激或腐蚀 无数据资料 呼吸道或皮肤过敏 无数据资料 生殖细胞突变性 无数据资料 致癌性 IARC: 2B - 第2B组：可能对人类致癌 (Tetrasodium 3,3'-[(3,3'-dimethyl[1,1'-biphenyl]-4,4'- diyl)bis(azo)]bis[5-amino-4-hydroxynaphthalene-2,7-disulphonate]) 生殖毒性 无数据资料 特异性靶器官系统毒性（一次接触） 无数据资料 特异性靶器官系统毒性（反复接触） 无数据资料 吸入危险 无数据资料 潜在的健康影响 吸入吸入可能有害。 可能引起呼吸道刺激。 摄入如服入是有害的。 皮肤如果通过皮肤吸收可能是有害的。 可能引起皮肤刺激。 眼睛可能引起眼睛刺激。 接触后的征兆和症状 据我们所知，此化学，物理和毒性性质尚未经完整的研究。 附加说明 化学物质毒性作用登记: 无数据资料 模块12. 生态学资料 12.1 生态毒性 无数据资料 12.2 持久存留性和降解性 无数据资料 12.3 潜在的生物蓄积性 无数据资料 12.4 土壤中的迁移性 无数据资料 12.5 PBT 和 vPvB的结果评价 无数据资料 12.6 其它不利的影响 无数据资料 模块13. 废弃处置 13.1 废物处理方法 产品 将剩余的和未回收的溶液交给处理公司。 受污染的容器和包装 作为未用过的产品弃置。 模块14. 运输信息 14.1 联合国危险货物编号 欧洲陆运危规: -国际海运危规: -国际空运危规: - 14.2 联合国（UN）规定的名称 欧洲陆运危规: 非危险货物 国际海运危规: 非危险货物 国际空运危规: 非危险货物 14.3 运输危险类别 欧洲陆运危规: -国际海运危规: -国际空运危规: - 14.4 包裹组 欧洲陆运危规: -国际海运危规: -国际空运危规: - 14.5 环境危险 欧洲陆运危规: 否国际海运危规 海运污染物: 否国际空运危规: 否 14.6 对使用者的特别提醒 无数据资料 模块 15 - 法规信息 N/A 模块16 - 其他信息 N/A

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : QJ6475000 CHEMICAL NAME : 2,7-Naphthalenedisulfonic acid, 3,3'-((3,3'-dimethyl-4,4'-biphenylylene)bis(azo))bis( 5- amino-4-hydroxy-, tetrasodium salt CAS REGISTRY NUMBER : 72-57-1 LAST UPDATED : 199710 DATA ITEMS CITED : 82 MOLECULAR FORMULA : C34-H28-N6-O14-S4.4Na MOLECULAR WEIGHT : 964.88 WISWESSER LINE NOTATION : L66J BQ DSWQ HSWQ JZ CNUNR B D- 2 &-NA- 4 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 6200 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 300 mg/kg TOXIC EFFECTS : Lungs, Thorax, or Respiration - acute pulmonary edema TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 300 mg/kg TOXIC EFFECTS : Lungs, Thorax, or Respiration - acute pulmonary edema TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 300 mg/kg TOXIC EFFECTS : Lungs, Thorax, or Respiration - acute pulmonary edema TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 350 mg/kg TOXIC EFFECTS : Lungs, Thorax, or Respiration - acute pulmonary edema TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 267 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 328 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rabbit DOSE/DURATION : 400 mg/kg TOXIC EFFECTS : Lungs, Thorax, or Respiration - acute pulmonary edema TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rabbit DOSE/DURATION : 100 mg/kg TOXIC EFFECTS : Lungs, Thorax, or Respiration - acute pulmonary edema TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - guinea pig DOSE/DURATION : 250 mg/kg TOXIC EFFECTS : Lungs, Thorax, or Respiration - acute pulmonary edema TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - guinea pig DOSE/DURATION : 300 mg/kg TOXIC EFFECTS : Lungs, Thorax, or Respiration - acute pulmonary edema TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 630 mg/kg/43W-I TOXIC EFFECTS : Tumorigenic - Carcinogenic by RTECS criteria Tumorigenic - tumors at site of application TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 250 mg/kg/10W-I TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Blood - lymphoma, including Hodgkin's disease TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 7500 mg/kg/86W-I TOXIC EFFECTS : Tumorigenic - neoplastic by RTECS criteria Liver - tumors Tumorigenic - tumors at site of application TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 1275 mg/kg/34W-I TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Liver - tumors Blood - leukemia TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 1300 mg/kg/1Y-I TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Liver - tumors Blood - lymphoma, including Hodgkin's disease TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 300 mg/kg/6W-I TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Liver - tumors Blood - lymphoma, including Hodgkin's disease TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Parenteral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 620 mg/kg/31W-I TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Liver - tumors TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Unreported SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 700 mg/kg/4W-I TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Liver - tumors TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 150 mg/kg SEX/DURATION : female 7-9 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 40 mg/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 12500 ug/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - Central Nervous System TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 12500 ug/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - body wall TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 30 mg/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 14 mg/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - eye/ear TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 10 mg/kg SEX/DURATION : female 7 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - behavioral TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 50 mg/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 50 mg/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 50 mg/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 50 mg/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Specific Developmental Abnormalities - Central Nervous System TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 15 mg/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral DOSE : 5 mg/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral DOSE : 50 mg/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral DOSE : 150 mg/kg SEX/DURATION : female 8-10 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported DOSE : 225 mg/kg SEX/DURATION : female 7-9 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intrauterine DOSE : 2500 ug/kg SEX/DURATION : female 6 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 100 mg/kg SEX/DURATION : female 6 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 66667 ug/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - body wall TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 66667 ug/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 1 gm/kg SEX/DURATION : female 8-12 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 100 mg/kg SEX/DURATION : female 7 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - other developmental abnormalities TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 25 mg/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - other developmental abnormalities TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 160 mg/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Specific Developmental Abnormalities - musculoskeletal system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 45 mg/kg SEX/DURATION : female 6-14 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 45 mg/kg SEX/DURATION : female 6-14 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetal death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 150 mg/kg SEX/DURATION : female 1 day(s) pre-mating female 2-7 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - gastrointestinal system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 150 mg/kg SEX/DURATION : female 1 day(s) pre-mating female 2-7 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 100 mg/kg SEX/DURATION : female 10 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Specific Developmental Abnormalities - gastrointestinal system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 40 mg/kg SEX/DURATION : female 11 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Maternal Effects - parturition TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 40 mg/kg SEX/DURATION : female 11 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - body wall TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 40 mg/kg SEX/DURATION : female 11 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral DOSE : 33 mg/kg SEX/DURATION : female 11 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 20 ug/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 20 ug/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - homeostasis TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 130 ug/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 900 ug/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - other developmental abnormalities TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 25 mg/kg SEX/DURATION : female 18 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 25 mg/kg SEX/DURATION : female 13 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - body wall TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 50 mg/kg SEX/DURATION : female 13 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - urogenital system TYPE OF TEST : Unscheduled DNA synthesis TYPE OF TEST : Cytogenetic analysis MUTATION DATA TYPE OF TEST : Unscheduled DNA synthesis TEST SYSTEM : Rodent - hamster Liver DOSE/DURATION : 100 umol/L REFERENCE : MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 136,255,1984 *** REVIEWS *** IARC Cancer Review:Animal Sufficient Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 8,267,1975 IARC Cancer Review:Human No Adequate Data IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 8,267,1975 IARC Cancer Review:Group 2B IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,56,1987 TOXICOLOGY REVIEW ADTEAS Advances in Teratology. (New York, NY) V.1-5, 1966-72. Discontinued. Volume(issue)/page/year: 1,131,1966 TOXICOLOGY REVIEW CLPTAT Clinical Pharmacology and Therapeutics (St. Louis). (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1960- Volume(issue)/page/year: 5,480,1964 TOXICOLOGY REVIEW ARVPAX Annual Review of Pharmacology. (Palo Alto, CA) V.1-15, 1961-75. For publisher information, see ARPTDI. Volume(issue)/page/year: 5,447,1965 TOXICOLOGY REVIEW JOPDAB Journal of Pediatrics. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63141) V.1- 1932- Volume(issue)/page/year: 59,1,1961 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - M2160 No. of Facilities: 62 (estimated) No. of Industries: 3 No. of Occupations: 11 No. of Employees: 1759 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - M2160 No. of Facilities: 55 (estimated) No. of Industries: 1 No. of Occupations: 3 No. of Employees: 813 (estimated) No. of Female Employees: 623 (estimated)

安全

• 符号: GHS08
• 信号词: Danger
• 危害声明: H350
• 警示性声明: P201-P308 + P313
• 个人防护装备: Eyeshields;full-face respirator (US);Gloves;multi-purpose combination respirator cartridge (US);type ABEK (EN14387) respirator filter
• 危害码 (欧洲): T:Toxic;
• 风险声明 (欧洲): R45
• 安全声明 (欧洲): S53-S45
• 危险品运输编码: 2811
• WGK德国: 3
• RTECS号: QJ6475000
• 海关编码: 32041400

合成路线

90-20-0 ~% 72-57-1

文献：Industrial and Engineering Chemistry, , vol. 17, p. 1289,1290 Chem. Zentralbl., , vol. 97, # I p. 1885

上下游产品

上游产品  1
90-20-0
下游产品  0

制备

由3，3'-二甲基联苯胺用亚硝酸钠与盐酸重氮化后，在碱性介质中与H酸进行偶合，而后经盐析、过滤及干燥而得。

海关

海关编码	32041400